MLXIPL and metabolic syndrome: ChREBP and SREBP-1c play a synergic role and regulate the genes expression of glycolytic and lipogenic pathways (61); ChREBP is stimulated by glucose; SREBP-1c is activated by insulin. Both factors regulate FA.synthesis. The upregulation of these factors favors hepatic steatosis, IR and the progression of MetS (62, 63)